NovaDigm Therapeutics, Inc. (Grand Forks, ND) and the University of North Dakota have entered into a research agreement whereby NovaDigm provides funding for vaccine-related research projects at UND.Â UND has released a Request for Proposals and expects to receive research proposals from its biomedical faculty by Jan. 7, 2011.Â Â The partners will work together to choose the best proposals to receive funding.
â€œI am extremely impressed by NovaDigmâ€™s willingness to fund projects with the biomedical research faculty at UND in this collaboration.Â Â This is a prime example of an effective public-private partnership, and we are pleased that NovaDigm has the confidence in UND to provide this funding,â€ said Dr. Phyllis Johnson, UND Vice President for Research and Economic Development.
â€œOur interactions with faculty members in the Medical School revealed several areas of mutual interest, making this program very attractive to us,â€ said Dr. John Hennessey, NovaDigmâ€™s Vice President of Research and Development.Â â€œWe are looking forward to turning some of these innovative ideas into active scientific collaborations.â€
Â NovaDigm stands to benefit if valuable intellectual property is developed with this funding, as the University has agreed to offer them an option to take a royalty-bearing license for discoveries made through this program.
NovaDigm is developing innovative vaccines to protect patients from fungal and bacterial infections, which can be life-threatening and drug resistant. The Companyâ€™s founding scientists from the LA BioMed Institute at Harbor-UCLA Medical Center are recognized leaders in the field of infectious disease and the emerging threat of â€œsuperbugs.â€ NovaDigmâ€™s lead product candidates target Candida, a fungal pathogen, and Staphylococcus aureus (S. aureus), including MRSA. Based in North Dakota’s Red River Valley Research Corridor with additional research activities at LA BioMed, NovaDigm has received funding from Domain Associates, a leading health care venture capital firm, and collaborates with multiple government agencies.Â NovaDigmâ€™s efforts are focused on development of our lead Candida-Staphylococcal vaccine, NDV-3, which is scheduled to begin Phase I clinical studies in 2010. The Company intends to bring this vaccine into clinical development and seek partners for manufacturing and commercialization. NovaDigm is assessing additional bacterial and fungal vaccine antigens to expand its product candidate pipeline.Â Our facility in Grand Forks, North Dakota encompasses 5,000 sq. ft. of laboratory and office space. It is located in the REAC1 building adjacent to the University of North Dakota campus.